TrovaGene Inc. (TROV)

0.76
NASDAQ : Health Technology
Prev Close 0.77
Day Low/High 0.76 / 0.80
52 Wk Low/High 0.65 / 7.68
Avg Volume 1.41M
Exchange NASDAQ
Shares Outstanding 22.99M
Market Cap 17.71M
EPS -8.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trovagene Announces Third Quarter 2018 Highlights And Financial Results

Trovagene Announces Third Quarter 2018 Highlights And Financial Results

SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Trovagene, Inc.

Trovagene To Present Data From Lead Clinical Program Of Onvansertib In Acute Myeloid Leukemia At The 60th American Society Of Hematology Annual Meeting

Trovagene To Present Data From Lead Clinical Program Of Onvansertib In Acute Myeloid Leukemia At The 60th American Society Of Hematology Annual Meeting

Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard-of-care chemotherapy may represent a new treatment option in AML

Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage Of NPM1 Mutations By U.S. Patent And Trademark Office

Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage Of NPM1 Mutations By U.S. Patent And Trademark Office

New patent claims strengthen patent estate revenue Aligns with Onvansertib Clinical Development and Biomarker Strategy in AML

Trovagene To Provide Update On Onvansertib Clinical Development Program On Wednesday, October 24, 2018

Trovagene To Provide Update On Onvansertib Clinical Development Program On Wednesday, October 24, 2018

-Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT

Trovagene Announces Exclusive License Agreement With MIT For Combination Therapy Of Anti-Androgens And Polo-like Kinase Inhibitors In Prostate Cancer

Trovagene Announces Exclusive License Agreement With MIT For Combination Therapy Of Anti-Androgens And Polo-like Kinase Inhibitors In Prostate Cancer

Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib

Trovagene Announces Completion Of Dosing Cohort Of Patients Treated With Onvansertib In Combination With Decitabine In Ongoing Phase 1b/2 AML Trial

Trovagene Announces Completion Of Dosing Cohort Of Patients Treated With Onvansertib In Combination With Decitabine In Ongoing Phase 1b/2 AML Trial

Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial

Trovagene Announces Participation At The MicroCap Conference On October 1st And 2nd At The Essex House In New York City

Trovagene Announces Participation At The MicroCap Conference On October 1st And 2nd At The Essex House In New York City

Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones

Trovagene Announces Predictive Clinical Biomarker Approach To Identify Acute Myeloid Leukemia (AML) Patients Most Likely To Respond To Onvansertib

Trovagene Announces Predictive Clinical Biomarker Approach To Identify Acute Myeloid Leukemia (AML) Patients Most Likely To Respond To Onvansertib

Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response

Trovagene Announces Completion Of Second Dosing Cohort Of Patients Treated With Onvansertib (PCM-075) In Ongoing Phase 1b/2 AML Trial

Trovagene Announces Completion Of Second Dosing Cohort Of Patients Treated With Onvansertib (PCM-075) In Ongoing Phase 1b/2 AML Trial

Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial

Trovagene Receives USAN Approval For "Onvansertib" As Nonproprietary Name For First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

Trovagene Receives USAN Approval For "Onvansertib" As Nonproprietary Name For First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

Onvansertib's product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy and safety in patients with various types of cancer

Trovagene Announces Second Quarter 2018 Highlights And Financial Results

Trovagene Announces Second Quarter 2018 Highlights And Financial Results

SAN DIEGO, Aug. 3, 2018 /PRNewswire/ -- Trovagene, Inc.

Trovagene Presents Outlook For Second Half Of 2018

Trovagene Presents Outlook For Second Half Of 2018

SAN DIEGO, July 9, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today provided an update on key...

Trovagene Announces Preliminary Clinical Data From First Dosing Cohort Demonstrating Durable Treatment Effect Of PCM-075 In Combination With Cytarabine Or Decitabine In Patients With Relapsed Or Refractory AML

Trovagene Announces Preliminary Clinical Data From First Dosing Cohort Demonstrating Durable Treatment Effect Of PCM-075 In Combination With Cytarabine Or Decitabine In Patients With Relapsed Or Refractory AML

Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia (AML)

Trovagene Announces Leadership Change

Trovagene Announces Leadership Change

William Welch has resigned as CEO and Director

Trovagene Announces The Start Of Recruitment And Enrollment For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® In Patients With MCRPC

Trovagene Announces The Start Of Recruitment And Enrollment For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® In Patients With MCRPC

Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trovagene Announces Completion Of First Dosing Cohort Of Patients Treated With PCM-075 In Combination With Decitabine In Ongoing Phase 1b/2 AML Trial

Trovagene Announces Completion Of First Dosing Cohort Of Patients Treated With PCM-075 In Combination With Decitabine In Ongoing Phase 1b/2 AML Trial

Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial

Trovagene, Inc. Announces Closing Of $18 Million Public Offering

Trovagene, Inc. Announces Closing Of $18 Million Public Offering

SAN DIEGO, June 12, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced the closing of its...

Trovagene, Inc. Announces Pricing Of $18 Million Public Offering

Trovagene, Inc. Announces Pricing Of $18 Million Public Offering

SAN DIEGO, June 7, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, today announced  the pricing of an...

Trovagene, Inc. Announces Reverse Stock Split

SAN DIEGO, May 31, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, announced today, a reverse split of its...

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 16.3% Higher For TROV

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TrovaGene (TROV) Is Today's Strong On High Volume Stock

TrovaGene (TROV) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc.

TheStreet Quant Rating: D- (Sell)